Ionis Partner Roche Reports Sefaxersen Reduced Proteinuria 43.1% in Phase 3 IgAN Study
Roche’s Phase 3 study found investigational sefaxersen reduced proteinuria by 43.1% versus placebo at 37 weeks in adults with IgA nephropathy, Ionis reported.
Ionis reported that partner Roche’s Phase 3 study found investigational sefaxersen reduced proteinuria by 43.1% versus placebo at 37 weeks in adults with IgA nephropathy.Key Highlights:Original SEC Filing: IONIS PHARMACEUTICALS INC [ IONS ] - 8-K - Oct. 23, 2026This is an AI-powered summary. It may…